Literature DB >> 22898445

Excited delirium following use of synthetic cathinones (bath salts).

Thomas M Penders1, Richard E Gestring, Dmitry A Vilensky.   

Abstract

Synthetic analogs of the cathinone molecule have seen increasing recreational use as substitutes for cocaine, 3,4-methylenedioxymethamphetamine (ecstasy) and methamphetamine. Repeated use of these drugs is associated with a paranoid hallucinatory delirium. A subset of patients using these substances develops a syndrome of extreme agitation and violent behavior that has been reported following the use of other stimulant drugs that also produce rapid changes in brain monoamines. This syndrome, characterized as "excited delirium," presents to the acute care setting with a challenging combination of paranoia, severe agitation and violent behavior. These patients frequently suffer from dehydration, skeletal muscle damage and renal failure that may lead to multiorgan failure and death. Management of these individuals requires careful consideration of the consequences of interventions commonly implemented in medical settings to control dangerous aggressive behavior.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22898445     DOI: 10.1016/j.genhosppsych.2012.06.005

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  18 in total

1.  Investigation of "bath salts" use patterns within an online sample of users in the United States.

Authors:  Patrick S Johnson; Matthew W Johnson
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

2.  Bath salts-induced psychosis: a case report.

Authors:  Vikas Mangewala; Sajjad R Sarwar; Kavit Shah; Tanvir Singh
Journal:  Innov Clin Neurosci       Date:  2013-02

3.  Awash in a sea of 'bath salts': implications for biomedical research and public health.

Authors:  Michael H Baumann
Journal:  Addiction       Date:  2014-07-01       Impact factor: 6.526

4.  Sex differences in α-pyrrolidinopentiophenone (α-PVP)-induced taste avoidance, place preference, hyperthermia and locomotor activity in rats.

Authors:  Katharine H Nelson; Hayley N Manke; Aikerim Imanalieva; Kenner C Rice; Anthony L Riley
Journal:  Pharmacol Biochem Behav       Date:  2019-08-21       Impact factor: 3.533

5.  Locomotor activity and discriminative stimulus effects of five novel synthetic cathinone analogs in mice and rats.

Authors:  Michael B Gatch; Sean B Dolan; Michael J Forster
Journal:  Drug Alcohol Depend       Date:  2019-04-06       Impact factor: 4.492

6.  Comparing rewarding and reinforcing properties between 'bath salt' 3,4-methylenedioxypyrovalerone (MDPV) and cocaine using ultrasonic vocalizations in rats.

Authors:  Steven J Simmons; Ryan A Gregg; Fionya H Tran; Lili Mo; Eva von Weltin; David J Barker; Taylor A Gentile; Lucas R Watterson; Scott M Rawls; John W Muschamp
Journal:  Addict Biol       Date:  2016-12-01       Impact factor: 4.280

Review 7.  The syndrome of excited delirium.

Authors:  James R Gill
Journal:  Forensic Sci Med Pathol       Date:  2014-02-14       Impact factor: 2.007

8.  Effects of the second-generation "bath salt" cathinone alpha-pyrrolidinopropiophenone (α-PPP) on behavior and monoamine neurochemistry in male mice.

Authors:  Azizi Ray; Neha Milind Chitre; Cedrick Maceo Daphney; Bruce E Blough; Clinton E Canal; Kevin Sean Murnane
Journal:  Psychopharmacology (Berl)       Date:  2018-10-01       Impact factor: 4.530

Review 9.  Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals.

Authors:  Nicolas Hohmann; Gerd Mikus; David Czock
Journal:  Dtsch Arztebl Int       Date:  2014-02-28       Impact factor: 5.594

10.  The clinical challenges of synthetic cathinones.

Authors:  Fabrizio Schifano; Flavia Napoletano; Davide Arillotta; Caroline Zangani; Liam Gilgar; Amira Guirguis; John Martin Corkery; Alessandro Vento
Journal:  Br J Clin Pharmacol       Date:  2020-02-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.